Engineered mesenchymal stem cells for premature ovarian insufficiency: Targeted strategies to overcome clinical translation bottlenecks (Review)

Premature ovarian insufficiency (POI) is defined as the decline of ovarian function before the age of 40 years, leading to loss of fertility and long‑term health damage. Currently, there is no treatment that can restore endogenous ovarian function. The ability of mesenchymal stem cells (MSCs) to repair ovarian function through paracrine signaling pathways has been demonstrated in preclinical studies; however, inconsistent clinical efficacy hinders their widespread application. This inconsistency originates from four well‑defined biological bottlenecks: i) Poor homing efficiency; ii) short survival time in the damaged microenvironment; iii) marked functional heterogeneity of cell populations; and iv) an unclear dose‑effect relationship. Over the years, based on an in‑depth understanding of MSC biology, engineered targeting strategies addressing the aforementioned bottlenecks have achieved systematic breakthroughs, including genetic modification to enhance homing capacity, preconditioning and three‑dimensional culture to prolong cell survival, functional subpopulation selection to improve efficacy consistency and biomaterial scaffolds to optimize local delivery. Notably, combined application of multiple strategies has shown synergistic effects in POI animal models. Early‑phase clinical studies have preliminarily confirmed the safety and feasibility of engineered MSC therapies; nevertheless, clinical translation still faces challenges such as large‑scale production of engineered products, validation of potency markers and long‑term safety monitoring. The present review systematically summarizes the research progress of these targeting strategies, aiming to provide a theoretical basis for establishing standardized and reproducible engineered MSC therapeutic protocols, and to promote the evolution of POI treatment from empirical attempts towards precision medicine.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Medicine
Published
2026-11-20
DOI
https://doi.org/10.3892/ijmm.2026.6062
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Engineered mesenchymal stem cells for premature ovarian insufficiency: Targeted strategies to overcome clinical translation bottlenecks (Review)

Wenyi Mi, Qingge Jia, Tian Tian, Qi Cao et al.
2 links
International Journal of Molecular Medicine
Mesenchymal stem cell research
article

Engineered mesenchymal stem cells for premature ovarian insufficiency: Targeted strategies to overcome clinical translation bottlenecks (Review)

Wenyi Mi, Qingge Jia, Tian Tian, Qi Cao, Juncheng Yao, Xiangyu Guo, Xiunan Luo
article en

Abstract

Premature ovarian insufficiency (POI) is defined as the decline of ovarian function before the age of 40 years, leading to loss of fertility and long‑term health damage. Currently, there is no treatment that can restore endogenous ovarian function. The ability of mesenchymal stem cells (MSCs) to repair ovarian function through paracrine signaling pathways has been demonstrated in preclinical studies; however, inconsistent clinical efficacy hinders their widespread application. This inconsistency originates from four well‑defined biological bottlenecks: i) Poor homing efficiency; ii) short survival time in the damaged microenvironment; iii) marked functional heterogeneity of cell populations; and iv) an unclear dose‑effect relationship. Over the years, based on an in‑depth understanding of MSC biology, engineered targeting strategies addressing the aforementioned bottlenecks have achieved systematic breakthroughs, including genetic modification to enhance homing capacity, preconditioning and three‑dimensional culture to prolong cell survival, functional subpopulation selection to improve efficacy consistency and biomaterial scaffolds to optimize local delivery. Notably, combined application of multiple strategies has shown synergistic effects in POI animal models. Early‑phase clinical studies have preliminarily confirmed the safety and feasibility of engineered MSC therapies; nevertheless, clinical translation still faces challenges such as large‑scale production of engineered products, validation of potency markers and long‑term safety monitoring. The present review systematically summarizes the research progress of these targeting strategies, aiming to provide a theoretical basis for establishing standardized and reproducible engineered MSC therapeutic protocols, and to promote the evolution of POI treatment from empirical attempts towards precision medicine.

International Journal of Molecular MedicineVol. 59(1)
University of Electronic Science and Technology of China (CN), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon